metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

breast cancer - HER2-positive
es-BC - HER2 positive - (neo)adjuvant (NA) 5
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1) 5
la/mBC - HER2 positive - 2nd Line (L2) 13

All treatments
HER inhibitor
HER2 inhibitor
pertuzumab based treatment
pertuzumab plus trastuzumab
pertuzumab plus trastuzumab plus docetaxel
trastuzumab based treatment
trastuzumab plus endocrine therapy
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab plus trastuzumab plus docetaxel

versus all
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs trastuzumab
vs trastuzumab plus chemotherapy
vs trastuzumab plus docetaxel

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open